This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
REPORT UPDATE JULY 2016: This report was published in March 2016, just before the Stop TB Partnership’s Global Drug Facility was due to update its price list for DR-TB drugs.
Dr-tb Drugs Under The Microscope
pdf — 632.83 KB